ArticleJournal of cardiothoracic surgery2026
Lactate-to-albumin ratio as a short‑term prognostic biomarker in atrial fibrillation.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile the lactate-to-albumin ratio (LAR) has shown prognostic relevance in general critical care populations, its utility in patients with atrial fibrillation (AF) remains underexplored. This study aimed to evaluate the association between LAR and 28-day all-cause mortality in patients with AF using the updated MIMIC-IV v3.1 database.
methodsThis retrospective cohort study included 3,962 patients with AF from the MIMIC-IV v3.1 database. Clinical data, including LAR, demographic characteristics, vital signs, laboratory parameters, and comorbidities, were analyzed for their associations with 28-day all-cause mortality. Univariate and multivariate Cox regression models were used to identify risk factors, whereas receiver operating characteristic (ROC) curves were used to evaluate the discriminative ability of the LAR. Subgroup analyses were performed to examine the robustness of the LAR across different clinical settings.
resultsThe LAR was independently associated with 28-day all-cause mortality in multivariate Cox regression analysis (HR: 1.12, 95% CI: 1.05-1.19, p < 0.001). The optimal LAR cutoff was 0.675, with a sensitivity of 56.2% and specificity of 63.8%. Kaplan‒Meier survival analysis confirmed that patients with higher LARs had significantly worse outcomes. Subgroup analyses revealed that the LAR maintained its prognostic value across most clinical subgroups, with some variability observed in patients receiving beta-blocker therapy.
conclusionsThe LAR may be useful as an auxiliary biomarker for risk stratification in critically ill patients with AF, particularly in those without confounding end-stage organ diseases. The identification of a risk inflection point (0.58) and an optimal cutoff (0.675) further suggests that LAR may be helpful for early risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.